Publication | Open Access
Discovery of Thioether-Cyclized Macrocyclic Covalent Inhibitors by mRNA Display
17
Citations
43
References
2024
Year
Drug TargetMolecular BiologyPeptide SciencePharmacotherapyChemical BiologyMolecular PharmacologyMedicinal ChemistryMacrocyclic PeptideMrna DisplayBiochemistryMedicineDiversity-oriented SynthesisBioconjugationMrna Display PlatformPharmacologyMacrocyclic PeptidesNatural SciencesPeptide LibraryRational Drug DesignMolecular DockingSmall MoleculesDrug Discovery
Macrocyclic peptides are promising scaffolds for the covalent ligand discovery. However, platforms enabling the direct identification of covalent macrocyclic ligands in a high-throughput manner are limited. In this study, we present an mRNA display platform allowing selection of covalent macrocyclic inhibitors using 1,3-dibromoacetone-vinyl sulfone (DBA-VS). Testcase selections on TEV protease resulted in potent covalent inhibitors with diverse cyclic structures, among which cTEV6-2, a macrocyclic peptide with a unique C-terminal cyclization, emerged as the most potent covalent inhibitor of TEV protease described to-date. This study outlines the workflow for integrating chemical functionalization─installation of a covalent warhead─with mRNA display and showcases its application in targeted covalent ligand discovery.
| Year | Citations | |
|---|---|---|
Page 1
Page 1